Sacituzumab |
| Katalog-Nr.GC65538 |
Sacituzumab ist ein humanisierter monoklonaler IgG1-AntikÖrper fÜr Anti-Trophoblasten-ZelloberflÄchenantigen 2 (Anti-Trop-2). Sacituzumab hatdasPotenzialfÜr die Erforschung von metastasiertem, dreifach negativem Brustkrebs.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1796566-95-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Trastuzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research[1].
[1]. A Bardia, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *